Safety Assessment of Co-Administered SARS-CoV-2 Vaccines in BALB/c Mice


Authors : Nshimirimana Jonas; Josephine W. Kimani; James Kimotho; Matthew Mutinda Munyao; Samson Muuo Nzou

Volume/Issue : Volume 9 - 2024, Issue 5 - May

Google Scholar : https://tinyurl.com/yc3dhmsa

Scribd : https://tinyurl.com/mukbka8c

DOI : https://doi.org/10.38124/ijisrt/IJISRT24MAY1831

Abstract : The onset of Coronavirus disease 2019 (COVID-19) in late 2019 presented a severe worldwide health crisis with widespread morbidity and mortality. Various vaccine platforms have been rapidly developed and approved for broad use in a swift and urgent response to prevent the transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. However, these vaccines differ significantly in terms of safety. Heterologous prime-boost vaccination enhances vaccine safety compared to homologous vaccination, although it could lead to a higher cumulative number of transient adverse events reported at each visit. Therefore, additional strategies are necessary to improve SARS- CoV-2 vaccine safety. Anecdotal options suggest that vaccine co-administration can significantly reduce these adverse effects and consequently, avert the need for frequent booster doses. This study reports the immunization outcomes against the SARS-CoV-2 virus by assessing the safety profiles of different SARS-CoV-2 vaccines co-administered in BALB/c mice. Vaccine combinations comprising mRNA/adenovirus26-vector, mRNA/inactivated, adenovirus26-vector/inactivated, and mRNA/adenovirus26-vector/inactivated vaccines were prepared in optimized doses, and their activities upon immunization evaluated in comparison with individual mRNA, adenovirus26-vectored and inactivated vaccines. Twenty-eight days post-immunization, safety profiles of the various treatments were evaluated through hematological and biochemical examination. Importantly, the co-administration regimens proved safe and were well-tolerated in mice, as evidenced by the normal hematological and biochemical values.

Keywords : mRNA Vaccine; Adenovirus26 Vector Vaccine; Inactivated Vaccine; SARS-Cov-2; Co-Administration; Safety; BALB/C Mice.

References :

  1. K. Dhama et al., ‘Coronavirus Disease 2019–COVID-19’, Clin Microbiol Rev, vol. 33, no. 4, Sep. 2020, doi: 10.1128/CMR.00028-20.
  2. Chang, X. Chang, Y. He, and K. J. K. Tan, ‘The determinants of COVID-19 morbidity and mortality across countries’, Sci Rep, vol. 12, no. 1, Dec. 2022, doi: 10.1038/s41598-022-09783-9.
  3. Richards et al., ‘Economic Burden of COVID-19: A Systematic Review’, ClinicoEconomics and Outcomes Research, vol. 14. Dove Medical Press Ltd, pp. 293–307, 2022. doi: 10.2147/CEOR.S338225.
  4. WHO, ‘WHO Coronavirus (COVID-19) Dashboard’, Geneva: World Health Organization, 2023, Accessed: Nov. 11, 2023. [Online]. Available: https://covid19.who.int/
  5. Haque and A. B. Pant, ‘Efforts at COVID-19 Vaccine Development: Challenges and Successes’, Vaccines (Basel), vol. 8, no. 4, p. 739, Dec. 2020, doi: 10.3390/vaccines8040739.
  6. H. Barouch, ‘Covid-19 Vaccines — Immunity, Variants, Boosters’, New England Journal of Medicine, vol. 387, no. 11, pp. 1011–1020, Sep. 2022, doi: 10.1056/nejmra2206573.
  7. Mevorach et al., ‘Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel’, New England Journal of Medicine, vol. 385, no. 23, pp. 2140–2149, Dec. 2021, doi: 10.1056/NEJMoa2109730.
  8. M. E. Oster et al., ‘Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021’, JAMA, vol. 327, no. 4, p. 331, Jan. 2022, doi: 10.1001/jama.2021.24110.
  9. K. E. Hanson et al., ‘Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink’, JAMA Netw Open, vol. 5, no. 4, p. e228879, Apr. 2022, doi: 10.1001/jamanetworkopen.2022.8879.
  10. M. Sarkar, I. Madabhavi, P. Quy, and M. Govindagoudar, ‘COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review’, Ann Thorac Med, vol. 17, no. 1, p. 1, 2022, doi: 10.4103/atm.atm_404_21.
  11. R. Rashedi, N. Samieefar, N. Masoumi, S. Mohseni, and N. Rezaei, ‘COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts’, J Med Virol, vol. 94, no. 4, pp. 1294–1299, Apr. 2022, doi: 10.1002/jmv.27463.
  12. R. L. Atmar et al., ‘Homologous and Heterologous Covid-19 Booster Vaccinations’, New England Journal of Medicine, vol. 386, no. 11, pp. 1046–1057, Mar. 2022, doi: 10.1056/NEJMoa2116414.
  13. S. Kanokudom et al., ‘Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine’, Vaccines (Basel), vol. 10, no. 1, p. 86, Jan. 2022, doi: 10.3390/vaccines10010086.
  14. P. Bonanni et al., ‘Vaccine co-administration in adults: An effective way to improve vaccination coverage’, Hum Vaccin Immunother, vol. 19, no. 1, Jan. 2023, doi: 10.1080/21645515.2023.2195786.
  15. P. Rzymski et al., ‘COVID-19 vaccine boosters: The good, the bad, and the ugly’, Vaccines (Basel), vol. 9, no. 11, Nov. 2021, doi: 10.3390/vaccines9111299.
  16. J. S. Woodworth et al., ‘A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin’, Nat Commun, vol. 12, no. 1, p. 6658, Nov. 2021, doi: 10.1038/s41467-021-26934-0.
  17. C. Sing et al., ‘COVID ‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study’, Am J Hematol, vol. 97, no. 4, pp. 470–480, Apr. 2022, doi: 10.1002/ajh.26478.
  18. P. S, R. R, and K. R, ‘Blood sample collection in small laboratory animals’, J Pharmacol Pharmacother, vol. 1, no. 2, pp. 87–93, Dec. 2010, doi: 10.4103/0976-500X.72350.
  19. Wang et al., ‘Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2’, Cell, vol. 182, no. 3, pp. 713-721.e9, Aug. 2020, doi: 10.1016/j.cell.2020.06.008.
  20. W. Santos et al., ‘Hematological and biochemical reference values for C57BL/6, Swiss Webster and BALB/c mice’, Braz J Vet Res Anim Sci, vol. 53, no. 2, p. 138, Jun. 2016, doi: 10.11606/issn.1678-4456.v53i2p138-145.
  21. Silva‐Santana et al., ‘Clinical hematological and biochemical parameters in Swiss, BALB/c, C57BL/6 and B6D2F1 Mus musculus’, Animal Model Exp Med, vol. 3, no. 4, pp. 304–315, Dec. 2020, doi: 10.1002/ame2.12139.
  22. Gomez-Rial, I. Rivero-Calle, A. Salas, and F. Martinon-Torres, ‘

    Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy

    ’, Infect Drug Resist, vol. Volume 13, pp. 2485–2493, Jul. 2020, doi: 10.2147/IDR.S258639.
  23. C. Shi and E. G. Pamer, ‘Monocyte recruitment during infection and inflammation’, Nat Rev Immunol, vol. 11, no. 11, pp. 762–774, Nov. 2011, doi: 10.1038/nri3070.
  24. G. Silva‐Santana et al., ‘Clinical hematological and biochemical parameters in Swiss, BALB/c, C57BL/6 and B6D2F1 Mus musculus’, Animal Model Exp Med, vol. 3, no. 4, pp. 304–315, Dec. 2020, doi: 10.1002/ame2.12139.
  25. J. Gomez-Rial, I. Rivero-Calle, A. Salas, and F. Martinon-Torres, ‘

    Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy

    ’, Infect Drug Resist, vol. Volume 13, pp. 2485–2493, Jul. 2020, doi: 10.2147/IDR.S258639.
  26. C. Shi and E. G. Pamer, ‘Monocyte recruitment during infection and inflammation’, Nat Rev Immunol, vol. 11, no. 11, pp. 762–774, Nov. 2011, doi: 10.1038/nri3070.
  27. J. Liu et al., ‘Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines’, Cell Discov, vol. 7, no. 1, p. 99, Oct. 2021, doi: 10.1038/s41421-021-00329-3.
  28. M. J. Cascio and T. G. DeLoughery, ‘Anemia’, Medical Clinics of North America, vol. 101, no. 2, pp. 263–284, Mar. 2017, doi: 10.1016/j.mcna.2016.09.003.
  29. M. Izak and J. B. Bussel, ‘Management of thrombocytopenia’, F1000Prime Rep, vol. 6, Jun. 2014, doi: 10.12703/P6-45.
  30. D. Al‐Ali et al., ‘Cardiovascular and haematological events post COVID‐19 vaccination: A systematic review’, J Cell Mol Med, vol. 26, no. 3, pp. 636–653, Feb. 2022, doi: 10.1111/jcmm.17137.
  31. H. Akiyama et al., ‘Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine’, IDCases, vol. 25, p. e01245, 2021, doi: 10.1016/j.idcr.2021.e01245.
  32. T. Iba and J. H. Levy, ‘Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination’, Trends Cardiovasc Med, vol. 32, no. 5, pp. 249–256, Jul. 2022, doi: 10.1016/j.tcm.2022.02.008.
  33. S. R. Ostrowski et al., ‘Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis’, Front Immunol, vol. 12, Nov. 2021, doi: 10.3389/fimmu.2021.779453.
  34. P. Rzymski, B. Perek, and R. Flisiak, ‘Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism’, Vaccines (Basel), vol. 9, no. 6, p. 559, May 2021, doi: 10.3390/vaccines9060559.
  35. E. J. Woo et al., ‘Thrombocytopenia after vaccination: Case reports to the US Vaccine Adverse Event Reporting System, 1990–2008’, Vaccine, vol. 29, no. 6, pp. 1319–1323, Feb. 2011, doi: 10.1016/j.vaccine.2010.11.051.
  36. M. E. Mingot-Castellano et al., ‘COVID-19 Vaccines and Autoimmune Hematologic Disorders’, Vaccines (Basel), vol. 10, no. 6, p. 961, Jun. 2022, doi: 10.3390/vaccines10060961.
  37. T. A. Woreta and S. A. Alqahtani, ‘Evaluation of Abnormal Liver Tests’, Medical Clinics of North America, vol. 98, no. 1, pp. 1–16, Jan. 2014, doi: 10.1016/j.mcna.2013.09.005.

The onset of Coronavirus disease 2019 (COVID-19) in late 2019 presented a severe worldwide health crisis with widespread morbidity and mortality. Various vaccine platforms have been rapidly developed and approved for broad use in a swift and urgent response to prevent the transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. However, these vaccines differ significantly in terms of safety. Heterologous prime-boost vaccination enhances vaccine safety compared to homologous vaccination, although it could lead to a higher cumulative number of transient adverse events reported at each visit. Therefore, additional strategies are necessary to improve SARS- CoV-2 vaccine safety. Anecdotal options suggest that vaccine co-administration can significantly reduce these adverse effects and consequently, avert the need for frequent booster doses. This study reports the immunization outcomes against the SARS-CoV-2 virus by assessing the safety profiles of different SARS-CoV-2 vaccines co-administered in BALB/c mice. Vaccine combinations comprising mRNA/adenovirus26-vector, mRNA/inactivated, adenovirus26-vector/inactivated, and mRNA/adenovirus26-vector/inactivated vaccines were prepared in optimized doses, and their activities upon immunization evaluated in comparison with individual mRNA, adenovirus26-vectored and inactivated vaccines. Twenty-eight days post-immunization, safety profiles of the various treatments were evaluated through hematological and biochemical examination. Importantly, the co-administration regimens proved safe and were well-tolerated in mice, as evidenced by the normal hematological and biochemical values.

Keywords : mRNA Vaccine; Adenovirus26 Vector Vaccine; Inactivated Vaccine; SARS-Cov-2; Co-Administration; Safety; BALB/C Mice.

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe